GC
AVNR

Guggenheim Capital’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Guggenheim Capital’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-83,079
Closed -$1.41M – 3148
2014
Q4 		$1.41M Buy
+83,079
New +$1.17M ﹤0.01% 1999
2014
Q2 		– Sell
-13,395
Closed -$49K – 3384
2014
Q1 		$49K Sell
13,395
-2,062
-13% -$7.86K ﹤0.01% 3138
2013
Q4 		$52K Buy
15,457
+2,367
+18% +$9.78K ﹤0.01% 3053
2013
Q3 		$56K Buy
13,090
+205
+2% +$971 ﹤0.01% 2927
2013
Q2 		$59K Buy
+12,885
New +$44.3K ﹤0.01% 2893

Guggenheim Capital's AVNR Position: Q1 2015 in Review

Guggenheim Capital sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 83,079 shares — an estimated $1.41M sold.

Guggenheim Capital first reported a position in AVNR in Q2 2013 and held it in 5 quarters. The position peaked at $1.41M in Q4 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

  • Guggenheim Capital reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
  • Guggenheim Capital sold 83,079 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $1.41M.
  • Guggenheim Capital first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 5 quarters.
  • Guggenheim Capital's AVANIR PHARMACEUTICALS, INC CL A position peaked at $1.41M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on Guggenheim Capital's 13F filing for Q1 2015, filed 15 May 2015.